Oncotarget

Research Papers:

The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma

Clémentine Sarkozy, Sarah Huet, Victoria E.H. Carlton, Bettina Fabiani, Alain Delmer, Fabrice Jardin, Marie-Helene Delfau-Larue, Maya Hacini, Vincent Ribrag, Stéphanie Guidez, Malek Faham and Gilles Salles _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:8765-8774. https://doi.org/10.18632/oncotarget.14448

Metrics: PDF 2908 views  |   HTML 3318 views  |   ?  


Abstract

Clémentine Sarkozy1,2, Sarah Huet2,3, Victoria E.H. Carlton4, Bettina Fabiani5, Alain Delmer6, Fabrice Jardin7, Marie-Helene Delfau-Larue8, Maya Hacini9, Vincent Ribrag10, Stéphanie Guidez11, Malek Faham4, Gilles Salles1,2

1Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service d’Hématologie, 69495 Pierre Bénite Cedex, France

2NSERM1052, CNRS 5286, Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Lyon-1, 69495 Pierre Bénite Cedex, France

3Hospices Civils De Lyon, Laboratoire d’Hématologie, Pierre Bénite, France

4Adaptive Biotechnologies Corp., South San Francisco, CA, USA

5Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France

6Service d’Hématologie, CHU de Reims, Reims, France

7Centre Henri Becquerel, Service d’Hématologie, Rouen, France

8Department of Biological Hematology and Immunology, Assistance Publique – Hôpitaux de Paris, Groupe Hospitalier Mondor, Créteil, France

9Centre Hospitalier de Chambery, Service d’Hématologie, Chambery, France

10Institut Gustave Roussy, Service d’Hématologie, Université Paris-Sacley, Villejuif, France

11Service d’Hématologie, CHU de Poitiers, France

Correspondence to:

Gilles Salles, email: [email protected]

Keywords: follicular lymphoma, circulating tumor DNA, prognostic factor, rituximab, maintenance

Received: December 02, 2016     Accepted: December 05, 2016     Published: January 02, 2017

ABSTRACT

Recent advances in next-generation sequencing (NGS) have enabled the quantitation of circulating tumour DNA (ctDNA) encoding the clonal rearranged V(D)J immunoglobulin locus. We aimed to evaluate the clonal heterogeneity of follicular lymphoma (FL) in the tumour and the plasma at diagnosis and to assess the prognostic value of the ctDNA level. Plasma samples at diagnosis were available for 34 patients registered in the PRIMA trial (NCT00140582). One tumour clonotype or more could be detected for 29 (85%) and 25 (74%) patients, respectively, in the tumour or plasma samples. In 18 patients, several subclones were detected in the tumour (2 to 71 subclones/cases) and/or in the plasma (2 to 20 subclones/cases). In more than half of the cases, the distribution of subclones differed between the tumour and plasma samples, reflecting high clonal heterogeneity and diversity in lymphoma subclone dissemination. In multivariate analysis, a high level of ctDNA was the only independent factor associated with patients’ progression-free survival (HR 4, IC 95 (1.1-37), p=.039). In conclusion, an NGS-based immunosequencing method reveals the marked clonal heterogeneity of follicular lymphoma in patients with FL, and quantification of ctDNA at diagnosis represents a potential powerful prognostic biomarker that needs to be investigated in larger cohorts.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14448